VSV-EBOVAC: Vaccine Safety and Immunogenicity Signatures of Human Responses to VSV-ZEBOV | NLM

Disaster Information Management Research Center | NLM

VSV-EBOVAC: Vaccine Safety and Immunogenicity Signatures of Human Responses to VSV-ZEBOV

02/01/2019 12:00 AM EST

Source: Innovative Medicines Initiative (IMI). Published: 2/2019. This web page provides information about the development of a new vaccine, VSV-ZEBOV, which has proven to be highly effective against the Ebola virus. Partners in the project VSV-EBOVAC analyzed the data and samples from early-phase clinical trials of the vaccine to find out more about what happens to the body after immunization, and how, exactly, it confers protection. (Text)